ABSTRACT: Although the promising immunosuppressant, mycophenolic acid (MPA), has many desirable properties and is widely prescribed for organ transplant recipients, its high oral dosage requirement is not understood. Whereas previous Northern blot analysis by Basu and colleagues (2004) located the mRNAs encoding MPA primary metabolizers, UDP-glucuronosyltransferases (UGTs) 1A7, 1A8, 1A9, and 1A10, in human gastrointestinal (GI) tissues, in situ hybridization analysis of mRNAs found that the isozymes were restricted to the mucosal layer of various GI organs. Concomitantly, MPA was glucuronidated by microsomes isolated from normal adjoining specimens. Microsomal studies showed the highest relative rates of metabolism in esophagus, ileum, duod...
Renal ischaemia is associated with accumulation of fatty acids (FA) and mobilisation of arachidonic ...
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Mycophenolate mofetil (MMF), an...
A significant number of cancer patients treated with the topoisomerase inhibitor, irinotecan, experi...
The prodrug mycophenolate mofetil (MMF) is used clinically for prophylaxis of organ rejection in tra...
Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal transplantation. How...
Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal transplantation. How...
In solid organ transplant patients, it is important to maintain a fine balance between preventing re...
Mycophenolic acid (MPA) is an immunosuppressive agent commonly used after organ transplantation. Alt...
Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the...
Mycophenolic acid (MPA) is metabolized primarily by glucuronidation to form the biologically inactiv...
Glucuronidation is an important metabolic process of detoxification in all vertebrates. The reaction...
OTS167 is a potent maternal embryonic leucine zipper kinase inhibitor undergoing clinical testing as...
Mycophenolic acid (MPA) is a cornerstone immunosuppressant therapy in solid organ transplantation. M...
Glucuronidation, mediated by UDP-glucuronosyltransferase enzymes (UGTs), is a major phase II biotra...
Mycophenolic acid (MPA) is the cornerstone of most immunosuppressive drug regimens after organ trans...
Renal ischaemia is associated with accumulation of fatty acids (FA) and mobilisation of arachidonic ...
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Mycophenolate mofetil (MMF), an...
A significant number of cancer patients treated with the topoisomerase inhibitor, irinotecan, experi...
The prodrug mycophenolate mofetil (MMF) is used clinically for prophylaxis of organ rejection in tra...
Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal transplantation. How...
Mycophenolic acid (MPA) is an important immunosuppressant broadly used in renal transplantation. How...
In solid organ transplant patients, it is important to maintain a fine balance between preventing re...
Mycophenolic acid (MPA) is an immunosuppressive agent commonly used after organ transplantation. Alt...
Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the...
Mycophenolic acid (MPA) is metabolized primarily by glucuronidation to form the biologically inactiv...
Glucuronidation is an important metabolic process of detoxification in all vertebrates. The reaction...
OTS167 is a potent maternal embryonic leucine zipper kinase inhibitor undergoing clinical testing as...
Mycophenolic acid (MPA) is a cornerstone immunosuppressant therapy in solid organ transplantation. M...
Glucuronidation, mediated by UDP-glucuronosyltransferase enzymes (UGTs), is a major phase II biotra...
Mycophenolic acid (MPA) is the cornerstone of most immunosuppressive drug regimens after organ trans...
Renal ischaemia is associated with accumulation of fatty acids (FA) and mobilisation of arachidonic ...
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Mycophenolate mofetil (MMF), an...
A significant number of cancer patients treated with the topoisomerase inhibitor, irinotecan, experi...